ReviewFrontiers in chemistry2026
AI-driven drug reposition for pathogens: a new paradigm in pandemic preparedness.
Review in Frontiers in chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Faced with a severe outbreak of diseases caused by newly emerging and recurrent pathogens, the development cycle of traditional drugs is long, making it difficult to meet emergency needs. Drug repositioning has become a key strategy for rapidly providing therapies by exploring new therapeutic uses of approved drugs. However, traditional reposition methods have bottlenecks such as slow speed and strong randomness. Artificial intelligence (AI) is revolutionizing drug reposition by analyzing and integrating multi-source data with computational models, dramatically accelerating the discovery process. This article summarizes the core technological approaches of AI-driven drug reposition, including predictions based on network medicine, virtual screening through deep learning models, and association discovery via real-world data mining. Multiple successful cases are presented to verify their effectiveness. Although there are still challenges in terms of data quality, model interpretability, and clinical translation, AI will undoubtedly reshape our drug development paradigm for addressing future public health crises, serving as a pivotal engine for rapid response and precise intervention.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.